All In Biotech

Drug Trial Radar · NCT04586478

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 26, 2020

Primary completion

Mar 30, 2024

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Juventas Cell Therapy Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

  • single dose of CNCT19Biological

    Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Remission Rate (ORR), which includes Complete Remission (CR) and Partial Remission (PR)Time frame: At 3 months after infusion

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Boren Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Xinqiao Hospital of TMMU

    Chongqing, Chongqing Municipality, China · Recruiting

  • Guangdong Provincial Peoples' Hospital

    Guangzhou, Guangdong, China · Recruiting

  • SunYat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital, Tongji Medical College of HUST

    Wuhan, Hubei, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tongji Hospital of Tongji University

    Shanghai, Shanghai Municipality, China · Recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University school of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.